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ABSTRACT— Purpose: To describe the initial ex-
perience of state mandated prenatal HIV screening 
at a large community hospital. Methods: HIV 
screening was provided to all pregnant women as of 
October 1,1999. All HIV-positive women identified 
received aggressive ahtiretroviral therapy to reduce 
the likelihood for vertical transmission. Neonates 
were screened for HIV at zero, six, and 12 months of 
age. Results: Seven pregnant women (0.3%) and 
two additional family members tested positive for 
HIV. All seven infants born to the identified HIV-
positive women have tested negative for infection. 
We estimated that six of nine cases of HIV infection 
identified would have been missed under a policy of 
voluntary HIV screening. Conclusions: Universal 
screening for HIV in pregnancy is achievable and 
desirable and provides the best opportunity to mini-
mize the number of new neonatal HIV infections. 
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Introduction 
INFECTION with the Human Immunodeficiency Virus (HIV), the virus responsible for Acquired Immunodefi-
ciency Syndrome (AIDS) remains a significant public 
health concern. Although available drug therapies have 
greatly improved the quality of life and survival times for 
HIV-infected individuals, death from complications of 
the infection eventually occurs. Without a cure, prevent-
ing the spread of HIV infection is central in controlling the 
disease. To this end, avoidance of activities associated 
with HIV transmission is essential. 
Pregnant mothers infected with HIV can transmit the 
virus to their infant during the course of pregnancy and 
delivery. Vertical transmission of the virus from the HIV-
infected gravida to the neonate accounts for the majority 
of new pediatric HIV infections. This vertical transmis-
sion rate can be substantially reduced with aggressive 
antiretroviral treatment of the HIV-infected mother dur-
ing the antepartum and intrapartum period combined with 
neonatal treatment of exposed infants.1,2:3 To achieve this 
benefit, however, one must first identify all infected moth-
ers. Voluntary prenatal screening for HIV infection has 
improved the rate of antepartum HIV testing in the mother, 
but still many women go untested.4,5 In response to this 
deficiency of voluntary screening, the State of Connecti-
cut, in October 1999, implemented legislation advising 
health-care providers to inform patients that HIV screen-
ing was part of routine obstetrical care (State of Connecti-
cut, House Bill No. 7501; June 1999 Special Session, 
Public Act No. 99-2). The purpose of this study is to re-
port on the impact of mandatory prenatal HIV screening 
at a large community hospital during the initial 10 months 
following enactment of the legislation. 
VOLUME 67, NO. 1 
Materials and Methods 
In October 1999, statewide implementation of Con-
necticut House Bill # 7501 required health-care provid-
ers to inform their pregnant patients that HIV testing is 
part of routine obstetrical care. Pregnant women would 
be provided with pre- and post-test counseling and in-
formed of the confidentiality of the test result. The prin-
ciple features of this legislation regarding antenatal HIV 
screening were: 
1. Health-care providers giving prenatal care to pregnant 
women in this state shall inform her, or ascertain from 
the women's medical record that such information has 
already been provided to her, that HIV testing is part of 
routine prenatal care and shall inform her of the health 
benefits to herself and newborn of being tested for HIV 
infection; 
2. HIV testing shall be performed within 30 days of the 
first examination and again between 26-28 weeks ges-
tation or shortly thereafter; 
3. If such testing is not documented in the medical record 
at time of admission for delivery, HIV testing of the 
pregnant women will be performed in the absence of 
written objection; and 
4. Newborn HIV screening will be performed unless 
maternal HIV status is documented. 
A team comprised of counselors, a family nurse practi-
tioner, infectious disease, and maternal-fetal medicine spe-
cialists coordinated the prenatal HIV-screening program 
and supervised the treatment of alL pregnant HIV-posi-
tive women identified. Pregnant women were aggressively 
managed with highly active antiretroviral treatment. 
Zidovudine (AZT) was always a component of the an-
tepartum regimen. Change in medical management was 
based on response to therapy as determined by HIV viral 
load and maternal CD4 levels. In addition, AZT was ad-
ministered intrapartum and postnatally to the infant as per 
the Pediatric AIDS Clinical Trial Group 076 Study pro-
phylaxis regimen.1 Standard intrapartum practices to 
lessen the risks of vertical transmission were practiced, 
e.g. the avoidance of fetal scalp electrodes. Cesarean sec-
tion was not routinely performed; however, patients were 
counseled regarding the potential for reduced neonatal 
transmission with elective cesarean section. Neonatal HIV 
testing was performed at zero, six, and 12 months of life. 
The period of study is October 1999 through July 2000. 
Results 
A total of 2,352 infants were born to 2,239 mothers at 
our community-based, university affiliated teaching hos-
pital during the study period. The racial profile at our in-
stitution is as follows: white: 62%,hispanic: 17%, black: 
14%, other: 7%. The majority of our patients are insured 
(78%); 22% are uninsured or covered by medicaid. All 
women delivered during the study period were screened 
for HIV. Seven pregnant women (0.3%) tested positive 
for HIV infection. Six of seven women were identified 
prior to their admission for labor. The seventh patient, 
having refused voluntary HIV screening earlier in the preg-
nancy, tested positive for HIV on admission for labor. On 
follow-up testing, two additional family members of HIV-
infected women also tested positive: the 18-month old 
child of one patient and the spouse of another. Of the nine 
individuals detected, 8/9 had no prior knowledge of their 
HIV status. A single patient did not disclose her known 
HIV-positive status at her initial prenatal visit but acknowl-
edged her positive status after her initial HIV prenatal 
screen returned positive. 
The six HIV-positive pregnant patients detected 
antenatally agreed to treatment during pregnancy with 
highly active antiretroviral therapy (HAART) in addition 
to intrapartum, postnatal AZT treatment. Four of six pa-
tients received zidovidine/lamivudine (Combivir) and 
nevirapine (Viramune) antenatally. The HIV viral load was 
undetectable at term in three of these women and was 
reduced to 477 copies in the fourth. Three out of four of 
these women were delivered vaginally at term; the fourth 
(undetectable viral load) was delivered at term by repeat 
cesarean section. A fifth woman received antenatal treat-
ment with zidovidine/lamivudine (Combivir) and abacavir 
(Ziagen). Her HIV viral load was reduced to undetect-
able levels by term and she was delivered vaginally. A 
sixth patient initially treated with zidovidine/lamivudine 
(Combivir) and nevirapine (Viramune) showed persistent 
HIV viral load elevations and required the addition of 
nelfinavir (Viracept). Her HIV viral load was reduced to 
420 copies by term when she was delivered vaginally. 
The patient who tested positive for HIV on admission to 
labor received no antenatal or intrapartum treatment; how-
ever, her infant received neonatal AZT therapy once ma-
ternal HIV infection was documented. Her HIV viral load 
at time of diagnosis was 137,000 copies. All seven in-
fants have tested negative for HIV infection. 
Discussion 
Early in the history of HIV infection prior to proven 
drug therapies, anonymous neonatal screening was per-
formed primarily to establish the seroprevalence of HIV 
infection in pregnancy.6,7 Subsequently, with the advent 
of effective antiretroviral treatments that improved sur-
vival, attention was focused on the early identification of 
infected individuals. In pregnancy, voluntary HIV screen-
ing was advocated in an effort to identify HIV-infected 
women.8 With time it became clear that HIV-infected 
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gravidas could transmit the infection to their infants. Ver-
tical transmission was found to occur in up to 25% of 
neonates born to untreated HIV-infected mothers.9 In 1994, 
zidovidine therapy administered in the antenatal, intra-
partum, and neonatal period could reduce the rate of ma-
ternal-infant HIV transmission by two-thirds.1 Further 
additions to the HIV treatment armamentarium allowed 
for greater control of maternal HIV infection and led to 
further reductions in the vertical transmission rate. With 
multidrug therapy, maternal-infant transmission rates have 
been reduced to 1% to 2%.23 This remarkable success in 
preventing new cases of neonatal HIV infection can be 
realized only if the infected gravida is identified and 
treated. The nature of HIV infection and its public health 
implications demands a coordinated approach to limit the 
spread of the infection wherever possible. 
In the United States today, mandatory HIV counseling 
with voluntary screening of pregnant women is the most 
common form of antenatal screening performed. This 
screening approach followed the 1995 recommendation 
of the United States Public Health Service.8 Although this 
antenatal HIV screening policy has succeeded in identi-
fying many infected women, only 58% to 81 % of women 
consent to voluntary screening.4 The reasons for refusal 
of voluntary antenatal HIV screening are many but in-
clude both patient and physician factors. Some patients 
may decline voluntary screening based on a perception 
of no risk for HIV infection. Other patients, with a his-
tory of drug use and/or prior sex partners, may not ac-
knowledge such history and refuse voluntary screening 
out of fear of arousing suspicion in their current partner. 
Still other patients at high risk for HIV infection may de-
cline voluntary screening out of fear of testing positive 
for the infection. The counseling style of the individual 
physician may have a significant influence on the rate of 
acceptance of voluntary screening. Physicians who per-
ceive their patients to be without risk for HIV infection 















































*status unknown in two infants 
HIV screening may rj,ave low rates of patient acceptance 
for voluntary HIV screening. Conversely, physicians more 
familiar with the inadequacies of screening based on risk 
factors alone may be more committed to antenatal HIV 
screening and thus have a higher percentage of patients 
accepting testing.10 
The importance of identifying HIV-infected pregnant 
women and reducing neonatal HIV infection combined 
with the deficiencies of voluntary prenatal HIV screen-
ing led to a change in prenatal HIV screening in the state 
of Connecticut. A policy of universal prenatal HIV screen-
ing was readily integrated by the local health-care pro-
viders and universally accepted by patients in our institu-
tion. When fully implemented, this revised state policy 
of mandated prenatal screening would achieve the objec-
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best opportunity of preventing vertically acquired neona-
tal HIV infection. Prior to state mandated prenatal HIV 
screening, many patients attending the hospital based 
obstetrics clinic underwent voluntary screening. We as-
sumed that the three patients identified in this hospital-
based clinic would have been detected under a policy of 
voluntary prenatal HIV screening. We estimated the re-
maining six cases (66.7%) would have gone undetected 
under the prior policy of voluntary prenatal HIV screen-
ing. In the first 10 months of mandated prenatal HIV 
screening, seven pregnant women were screen positive 
for HIV. Assuming a 25% vertical transmission rate with-
out therapy, we estimated that two case of neonatal HIV 
infection were prevented with a policy of mandatory pre-
natal HIV screening; we estimate that one of these cases 
would have been missed under a policy of voluntary 
screening. The prevention of a single case of a lethal dis-
ease makes a strong argument for universal HIV screen-
ing in pregnancy. 
The impact of a policy of universal prenatal HIV screen-
ing combined with aggressive antepartum, intrapartum, 
and neonatal HIV therapy is reflected in our institutional 
numbers over the past 10 years (Table 1). Under a policy 
of voluntary screening (1992-1998), one to three cases 
of HIV in pregnancy were documented. With institution 
of universal screening, 15 cases were identified between 
1999-2000. Prior to AZT monotherapy for prevention of 
vertical transmission of HIV the vertical transmission rate 
at our hospital was 40% (2/5). With AZT monotherapy, 
the vertical transmission rate in infants with known fol-
low up was 29% (2/7). Since the utilization of HAART in 
pregnancy in 1997, only a single case tl/19,5.5%)of HIV 
infection has been documented in exposed neonates. The 
reduction in neonatal HIV infection documented at our 
institution has mirrored the success experienced statewide. 
In the years 1995-2000, the reported number of prenatal 
HIV cases has remained relatively constant (Table 2). A 
slight increase in the number of prenatal HIV infection 
was recorded in the first two years (1999,2000) of man-
dated prenatal HIV screening. In contrast, the rate of neo-
natal HIV infection has declined from 11.9% in 1995 to 
,1.9% after mandated HIV screening. In 2000, the first, 
full year of mandated prenatal HIV screening, all sixty 
neonates with known follow-up born to HIV-positive 
mothers have tested negative for the infection (Connecti-
cut Department of Public Health, Connecticut HIV/AIDS 
Statistics Through December 31, 2001, www.dph.state. 
ct.us/BCH/infectiousdise/aids_case_data.htm). 
Despite a marked reduction in the number of perinatally 
acquired HIV infants from a peak of 1,000-2,000 during 
the early 1990s, an estimated 300-400 babies continue to 
be born with-HIV yearly in the United States. Many of 
these infants are born to women who were not tested for 
HIV before delivery (CDC data, 2001). The initiative to-
wards universal prenatal HIV screening was outlined in 
the United States Public Health Service revised statement 
regarding HIV screening of pregnant women issued in 
2000." In our experience, universal screening for HIV in 
pregnancy was readily accepted by the informed patients 
and proved highly effective. As illustrated by the institu-
tional and statewide data presented, universal screening 
for HIV infection in pregnancy affords the best opportu-
nity to prevent many cases of neonatal HIV infection that 
continue to occur with voluntary prenatal HIV screening. 
Prevention of HIV is less costly than treatment. It is likely 
that a policy of universal screening for HIV in pregnancy 
may prove cost effective.12,13 The tremendous individual 
and societal burden of HIV infection warrants an aggres-
sive health-care policy to reduce the spread of the infec-
tion. The time for voluntary screening for HIV infection 
in pregnancy has passed. With the advent of effective 
antenatal and neonatal therapies to prevent new cases of 
neonatal HIV infection, the time for universal prenatal 
HIV screening has arrived. 
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